Last reviewed · How we verify
Phthalin (PHENOLPHTHALEIN)
Phenolphthalein, marketed as Phthalin, is a drug primarily indicated for headache, operating through the inhibition of thymidylate synthase, an enzyme crucial for DNA synthesis. Its key competitive advantage lies in its unique mechanism of action, distinguishing it from same-class competitors such as oxyphenisatine, bisacodyl, castor oil, and sodium picosulfate. The primary risk to Phenolphthalein is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PHENOLPHTHALEIN |
|---|---|
| Drug class | phenolphthalein |
| Target | Thymidylate synthase, Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Headache
- Rash
- Muscle Aches
- Itching
- Dizziness
- Confusion
- Diarrhea
Common side effects
Key clinical trials
- Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation (PHASE4)
- Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients (PHASE4)
- PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phthalin CI brief — competitive landscape report
- Phthalin updates RSS · CI watch RSS